跳至主要内容
临床试验/CTRI/2023/03/050626
CTRI/2023/03/050626尚未招募4 期

Evaluation Of Efficacy Of Doorvadi Cream In Paridagdha Chavi W.S.R To Atopic Dermatitis InPaediatric Age Group-A Randomized Clinical Trial

Mahant Digvijaynath Ayurved Chikitsalaya1 个研究点 分布在 1 个国家目标入组 196 人开始时间: 2023年3月20日最近更新:

试验速览

阶段
4 期
状态
尚未招募
发起方
入组人数
196
试验地点
1
主要终点
Reduced redness

研究概览

简要总结

Atopic  dermatitis (AD) is the most common chronic inflammatoryskin disorder in children the prevalence of AD has almost tripled in industrializedcountries during last three decade Approximate 15%-30% children are affected.Approximately 45% of cases of atopic dermatitis begin within 6 month of life 60%begins during first year 85% begins before 5 year of age. Up to 70% of childrenhave a reemission before adolescence.

Thenumber of AD      patient is beyond the level that can be dealt with atclinics and it is time to make an effort   toreduce the number of AD patients in the community

The introduction of topical steroids of varyingpotency has rendered the therapy of inflammatory coetaneous disorders moreeffective and less time-consuming. However, the usefulness of these has becomea double edged sword with constantly rising instances of abuse and misuseleading to serious local, systemic and psychological side effects.

Cornerstone of therapy of AD is tropical differentformulation because impaired skin barrier is pivotal in the pathogenesis of AD.

So it is a need of more radical approach through ayurveda to manage ADwith no side effect with help of herbal medicine in the form of cream make theherbal barrier on impaired skin

研究设计

研究类型
Interventional
分配方式
Computer generated randomization
盲法
Not Applicable

入排标准

年龄范围
6.00 Month(s) 至 12.00 Year(s)(—)
性别
All

入选标准

  • 1-Pre diagnosed case of atopic dermatitis 2-Having mild and moderate atopic dermatitis according to TIS Scoring.

排除标准

  • The exclusion criteria are as follows: (1) lesions with oozing, (2) oral administration of corticosteroids, immunosuppressant’s, or antibiotics 4 weeks prior to study entry, (3) administration of topical glucocortecoids, immunosuppressant’s, or antibiotics, or phototherapy, 2 weeks prior to study entry, (4) burn or trauma on the lesions, (5) active skin diseases without AD, (6) renal or liver dysfunction, (7) other uncontrolled chronic diseases, (8) participation in other clinical trials within 1 month of enrollment, (9) inability to understand the written consent or to engage in this study due to mental impairment or other emotional or mental problems, and (10) judgment by experts that the potential subject’s participation is inappropriate.

结局指标

主要结局

Reduced redness

时间窗: 7th day

次要结局

  • TIS score reduced(15th & 45th day)

研究者

发起方
Mahant Digvijaynath Ayurved Chikitsalaya
申办方类型
Private medical college

研究点 (1)

Loading locations...

相似试验